Seqster and PatientsLikeMe have announced a strategic partnership to integrate real-time electronic health record (EHR) data with patient engagement tools, aiming to significantly improve clinical research and patient outcomes.
In a strategic move aimed at transforming healthcare supply chains, TraceLink, a leading provider of digital supply chain solutions, has partnered with Tecsys, an industry leader in inventory and warehouse management systems.
In a significant move set to reshape the landscape of drug discovery, NovAliX, a leading Contract Research Organization (CRO) specializing in drug development, has entered a strategic partnership with Bruker, a global leader in scientific instruments.
As advanced therapies drive increasing market consolidation, the US giant Agilent Technologies has acquired the Canadian contract development and manufacturing organization (CDMO) BIOVECTRA for $925 million.
CatSci, a UK-based innovation partner for the development of pharmaceutical manufacturing processes, will be expanding its service offering with the acquisition of Reach Separations.
In a bold move set to reshape the global healthcare landscape, Asahi Kasei Corp. announced its intent to acquire Swedish drug maker Calliditas Therapeutics AB through a voluntary tender offer.
Walgreens and Boehringer Ingelheim have joined forces in a move to enhance diversity and accessibility in clinical trials, aiming to make participation more inclusive and equitable.
Adragos Pharma is a contract development and manufacturing organization (CDMO) that provides development and manufacturing services for drug products. It concentrates on small molecule dosage forms including sterile and non-sterile liquids, solids, and...
Precision oncology innovator SimBioSys and General Inception have joined forces in a strategic partnership aimed at revolutionizing cancer drug development.
Bora Pharmaceuticals Co., Ltd. yesterday (April 1) finalized the acquisition of Upsher-Smith Laboratories, Inc., a leading generics manufacturer based in Minnesota, U.S., from its previous owners, Sawai Group Holdings and Sumitomo Corporation of Americas.
Yesterday (March 18) PureTech Health plc announced the completion of the acquisition of its founded entity, Karuna Therapeutics, Inc., by Bristol Myers Squibb for a staggering $14 billion.
Announced today (January 25), Quibim, a company transforming imaging data into actionable predictions of cancer progression and treatment responses, has partnered with Merck KGaA.
Inceptua Group and Cycle Pharmaceuticals partnership will give access to Free Goods Partnership that gets medicine to patients with extremely rare genetic conditions, which they would be unable to access otherwise.
With innovative and flexible lab and manufacturing solutions being a critical success factor in drug development and delivery, SmartLabs, was delighted to announce the raise of $48 million series C financing.
An alliance between KBI Biopharma Inc., and Argonaut Manufacturing Services Inc., has been formed so biopharma clients can receive end-to-end drug substance and drug product manufacturing solutions.
Clinical-stage drug delivery and development company DelSiTech has made the biggest single financing round in its history with the successful completion of a €10 million deal.
Pharma giant, GSK, plans to invest £200 million ($253 million) into the UK over the next two years and has acquired Aiolos Bio for $1.1 billion (£870 million).
Evotec’s end-to-end integrated research and development platform will be able to advance drug discovery for two drug targets which is why it has joined forces with the Crohn’s & Colitis Foundation.
AION Labs, the first-of-its-kind venture studio today (January 8) announced its new partnership with Amiti Ventures, a leading early-stage venture capital firm in Israel.
Bristol Myers Squibb has announced it has acquired Karuna Therapeutics, Inc., for a total equity value of $14 billion or $12.7 billion net of estimated cash.
Decentralized clinical trials (DCTs) are gaining increasing interest as they have the potential to make clinical trial operations quicker, more efficient and more accessible to patients. Check out five DCT organizations that have raised big venture capital...
The pharmaceutical industry in 2023 has seen many investments, partnerships, acquisitions and more. As the year ends, industry leaders give the biggest trends to look for in 2024, with artificial intelligence being a hot topic.
A Life Sciences Advisory Board has been launched by Atropos Health, a company that translates data into personalized real-world insights across healthcare.
Definitive agreements with Fresenius Kabi have been signed by Prange Group and its affiliate Adragos Pharma for its sterile pharmaceutical production site in Halden, Norway.
Life sciences investment group and part of global investment firm Carlyle, Abingworth announced last week it had exceeded its $300 million target by $56 million.
A transaction between Citius Pharmaceuticals and TenX Keane which will result in the formation of Citius Oncology, Inc. is due to close in the first half of next year (2024).
A collaboration has been formed between the US pharmacy chain Walgreens and the Cardiovascular Research Foundation (CRF) to measure how prevalent valvular heart disease (VHD) is among older Americans.
Technology company, Medable Inc., offering services for modern clincal trials has joined forces with Pluto Health, a smart care coordination services company offering a health coordination platform.
Danaher is to acquire Abcam for $24 per share - a total enterprise value of approximately $5.7 billion representing approximately 40% more than Abcam's undisclosed share prices in May.
STARLIMS, a company that provides enterprise informatics solutions has acquired Labstep, a research and development (R&D) electronic laboratory notebook (ELN).
A company that ‘translates science into survival’ by developing new therapies has completed its acquisition of a technology company leading in artificial intelligence (AI) and machine learning (ML).
